Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Inclusion Criteria: * Human leukocyte antigen (HLA)-identical sibling donor * Myeloablative preparative regimen (i.e., \>= TBI 12.0 Gy, \>= busulfan (BU) 8.0 mg/kg PO, \>= BU 6.4 mg/kg intravenously (IV), \>= treosulfan 42 g/m\^2 IV) according to investigational study or standard treatment plan; other "myeloablative" preparative regimens are acceptable as long as they are approved by the principal investigator or designee * Transplantation of PBSC * Cyclosporine (CSP)-based postgrafting immunosuppression * Willingness to give informed consent * DONOR: Age \>= 18 years * DONOR: HLA genotypically identical sibling * DONOR: Willingness to give informed consent Exclusion Criteria: * Nonmyeloablative preparative regimen * Participation in an investigational study that has acute GVHD as the primary endpoint * The allogeneic PBSC donor has a contraindication to statin treatment * DONOR: Age \< 18 years * DONOR: Active liver disease (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] levels \> 2 times the upper limit of normal \[ULN\]) * DONOR: History of myopathy * DONOR: Hypersensitivity to atorvastatin * DONOR: Pregnancy * DONOR: Nursing mother * DONOR: Current serious systemic illness * DONOR: Concurrent treatment with strong inhibitors of hepatic cytochrome P450 (CYP) 3A4 (i.e. clarithromycin, erythromycin, protease inhibitors, azole antifungals) * DONOR: Current use of statin drug * DONOR: Failure to meet Fred Hutchinson Cancer Research Center (FHCRC) or local criteria for stem cell donation * DONOR: Total creatinine kinase \> 2 times the ULN